Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from August 29, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 27, 2025.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$82.40 Published $90.61 Target $103.74 Window close $104.94 Peak
$80.01 – $81.94Entry zone — fair-value band
$82.40Published — price the day we called it
$90.61Target — the price the thesis aimed for
$104.94Peak — highest point inside the window, not a realized return
$103.74Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 76 days.

Peak price
$104.94
peak on November 25, 2025 — not a realized return
Peak gain
+27.4%
peak, from the publication price
Window close
$103.74
end-of-window price, context only
Days to target
76
Window
August 29, 2025 – November 27, 2025

The thesis — published August 29, 2025

Predicted growth
+12%
over the measurement window
Target price
$90.61
the price the thesis aimed for
Entry zone
$80.01 – $81.94
the fair-value band we waited for
Price at publication
$82.40
published August 29, 2025
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck looks like a steady grower with fresh news that could lift interest. The about $10B Verona Pharma deal adds Ohtuvayre to its future lineup, and a strong 93% quality score backs the story. The price trend looks healthy, and more buyers seem active than usual. Over the next 0-3 months, investors may slowly price in this added pipeline strength, so buying small dips with a clear exit plan makes sense.

Primary drivers

  • Buying Verona Pharma adds a new lung drug (Ohtuvayre) to growth
  • Strong 93% quality score in recent news supports investor confidence
  • Price trend looks healthy, with more buyers stepping in than usual
  • Cancer treatments and vaccines remain strong, giving steady cash flow

How it played out

MRK: target reached in 76 days

Lyra published MRK at $82.40 on 2025-08-29 with a short-term thesis for 12% expected growth toward $90.61. The thesis pointed to the about $10B Verona Pharma deal, Ohtuvayre as added pipeline strength, a 93% quality score, a healthy price trend, more buyer activity than usual, and steady cash flow from cancer treatments and vaccines.

Inside the window, MRK reached the target in 76 days. The peak was $104.94 on 2025-11-25, with a 27.4% peak gain. It ended the window at $103.74. The thesis played out by the ledger's price test.

What happened during the window

On Oct. 30, 2025, Investors.com reported that Merck topped third-quarter expectations, with sales of $17.28 billion and adjusted earnings per share of $2.58. It also reported that Merck raised its yearly profit outlook and narrowed its sales guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals